Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

EZM0414 is an inhibitor of SET domain-containing protein 2 (SETD2; IC50 = 18 nM).1 It inhibits the proliferation of A549 non-small cell lung cancer (NSCLC) cells (EC50 = 57 nM). EZM0414 (15 and 30 mg/kg) decreases tumor volume in a KMS-11 multiple myeloma mouse xenograft model. It decreases cardiomyocyte levels of trimethylated lysine 36 on histone H3 (H3K36Me3) in a mouse model of heart failure with preserved ejection fraction (HFpEF) induced by a high-fat diet and L-NAME (Item No. 80210).2 EZM0414 also reduces lung congestion and cardiac hypertrophy in the same model.
WARNING This product is not for human or veterinary use.
1. Conformational-
2. Chromatin rewiring by SETD2 drives lipotoxic injury in cardiometabolic HFpEF. Circ. Res. 136(10), 1079-1095 (2025).